BiomX Inc. (PHGE)
0.55
-0.04 (-6.11%)
At close: Apr 04, 2025, 3:59 PM
0.55
0.20%
After-hours: Apr 04, 2025, 05:43 PM EDT
-6.11% (1D)
| Bid | 0.55 |
| Market Cap | 13.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.47 |
| PE Ratio (ttm) | -0.37 |
| Forward PE | -0.31 |
| Analyst | Buy |
| Ask | 0.6 |
| Volume | 158,159 |
| Avg. Volume (20D) | 113,645 |
| Open | 0.60 |
| Previous Close | 0.59 |
| Day's Range | 0.55 - 0.62 |
| 52-Week Range | 0.48 - 4.99 |
| Beta | 1.32 |
About PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2019
Employees 52
Stock Exchange AMEX
Ticker Symbol PHGE
Website https://www.biomx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 4077.26% from the latest price.
Stock Forecasts5 days ago
-2.34%
BiomX shares are trading lower after the company r...
Unlock content with
Pro Subscription
1 week ago
-11.05%
BiomX shares are trading lower on possible continued weakness after the company reported a FY24 EPS miss on Tuesday.
